title: Quality measures of imaging mass spectrometry aids in revealing long-term striatal protein changes induced by neonatal exposure to the cyanobacterial toxin β-N-methylamino-L-alanine (BMAA).
abstract: Many pathological processes are not directly correlated to dramatic alterations in protein levels. The changes in local concentrations of important proteins in a subset of cells or at specific loci are likely to play a significant role in disease etiologies, but the precise location might be unknown, or the concentration might be too small to be adequately sampled for traditional proteomic techniques. Matrix-assisted laser desorption ionization (MALDI) imaging mass spectrometry (IMS) is a unique analytical method that combines analysis of multiple molecular species and of their distribution in a single platform. As reproducibility is essential for successful biomarker discovery, it is important to systematically assess data quality in biologically relevant MALDI IMS experiments. In the present study, we applied four simple tools to study the reproducibility for individual sections, within-group variation, and between-group variation of data acquired from brain sections of 21 animals divided into three treatment groups. We also characterized protein changes in distinct regions of the striatum from six-month-old rats treated neonatally (postnatal days 9-10) with the cyanobacterial toxin β-N-methylamino-l-alanine (BMAA), which has been implicated in neurodegenerative diseases. The results showed that optimized experimental settings can yield high-quality MALDI IMS data with relatively low variation (14% to 15% coefficient of variance) that allow the characterization of subtle changes in protein expression in various subregions of the brain. This was further exemplified by the dose-dependent reduction of myelin basic protein in the caudate putamen and the nucleus accumbens of adult rats neonatally treated with BMAA (150 and 460 mg/kg). The reduction in myelin basic protein was confirmed through immunohistochemistry and indicates that developmental exposure to BMAA may induce structural effects on axonal growth and/or directly on the proliferation of oligodendrocytes and myelination, which might be important for the previously shown BMAA-induced long-term cognitive impairments.
authors.affiliation: Department of Pharmaceutical Biosciences, Uppsala University, 751 24 Uppsala, Sweden;
authors.forename: Oskar
authors.initials: O
authors.lastname: Karlsson
authors.forename: Jonas
authors.initials: J
authors.lastname: Bergquist
authors.forename: Malin
authors.initials: M
authors.lastname: Andersson
mesh_terms: D000599:Amino Acids, Diamino / Q000008:administration & dosage*; D000818:Animals; D000831:Animals, Newborn; D001369:Axons / Q000187:drug effects; D015415:Biomarkers / Q000378:metabolism; D049109:Cell Proliferation / Q000187:drug effects; D003342:Corpus Striatum / Q000187:drug effects*; D000087522:Cyanobacteria Toxins; D006801:Humans; D013058:Mass Spectrometry; D004676:Myelin Basic Protein / Q000096:biosynthesis* / Q000378:metabolism; D019636:Neurodegenerative Diseases; D009836:Oligodendroglia / Q000187:drug effects / Q000378:metabolism; D040901:Proteomics; D051381:Rats; D019032:Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
chemical_list: D000599:Amino Acids, Diamino; D015415:Biomarkers; D000087522:Cyanobacteria Toxins; D004676:Myelin Basic Protein; C001824:beta-N-methylamino-L-alanine